ClinicalTrials.gg
CompletedNCT02040597TRIPLE10Updated Oct 29, 2021

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.

A Phase 1 interventional study of Beclometasone/Formoterol/Glycopyrrolate in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Chiesi Farmaceutici S.p.A.. Completed at 2 sites in Poland. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
40 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive — none open to participants now, none under way, none of them phase 3. Beclomethasone · Pulmonary Disease, Chronic Obstructive.

Enrollment
3rd of 13
42 · median 24
Started
2014
with 2 others
Phase 1
3 of 13
none open now
Registered
7th of 13
by date
Lead sponsor
6 of 13
Chiesi Farmaceutici S.p.A.

Among the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive, this one is the 3rd largest by enrollment, is one of 3 that started in 2014, is one of 3 in phase 1, and was the 7th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

None of the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive is open now. The open studies under Pulmonary Disease, Chronic Obstructive, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing beclomethasone in Pulmonary Disease, Chronic Obstructive as a file.
02

Study summary

The study is performed to characterize the pharmacokinetics of glycopyrrolate bromide after single administration of CHF 5993 pressurised Metered Dose Inhaler (pMDI) in subjects with different level of renal impairment in comparison with matching healthy volunteers. Moreover, the safety and tolerability of the study drug will be also evaluated.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteers and
  • Subjects with mild, moderate and severe renal impairment

Exclusion criteria

Exclusion Criteria:

  • pregnant or lactating women
  • positive and hepatitis serology
  • history of drug abuse
  • history of to the products used in the trial
  • smokers
  • respiratory disease such as asthma and
  • concomitant disease that may introduce a risk for the subjects'safety
  • presence of kidney stones
  • dialysis
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    CHF5993 pMDI

    CHF 5993 pMDI (Beclometasone/Formoterol/Glycopyrrolate 100/6/25 mcg) 4 inhalations

    Drug: Beclometasone/Formoterol/Glycopyrrolate

Interventions

06

What researchers measure

Primary outcomes

  1. Glycopyrrolate area under the curve (AUC)

    AUC until the last quantifiable concentration (AUCt)

    Time frame: over 72 h after single administration

Secondary outcomes

  1. Glycopyrrolate other Pharmacokinetic parameters in plasma

    AUC until 72 h post dose (AUC0-72h), AUC extrapolated to infinity (AUCinf), maximum plasma concentratio (Cmax), time to maximum plasma concentration (tmax), half-life, clearance

    Time frame: Over 72 h after single administration

  2. B17MP and Formoterol pharmacokinetic parameters in plasma

    AUCt, AUC until 24 h post dose (AUC0-24h), AUCinf, Cmax, tmax, half-life, clearance

    Time frame: over 24 h after single administration

  3. BDP pharmacokinetic parameters in plasma

    AUCt, AUCinf, Cmax, tmax, half-life

    Time frame: over 24 h after single administration

  4. Urine Glycopyrrolate excretion (Ae)

    Time frame: over 72 h after single administration

  5. Urine formoterol excretion (Ae)

    Time frame: Over 24 h after single administration

  6. Adverse events

    This includes a period of 3 to 7 weeks (depending on duration of screening and follow-up periods), before and after the study drug administration

    Time frame: A period of 3 to 7 weeks (from screening visit to follow-up phone call)

  7. Vital signs

    systolic and diastolic blood pressure

    Time frame: over 24 h after single administration

  8. Electrocardiogram (ECG) parameters

    Heart rate (HR), time interval between ECG waves Q and T corrected for heart rate with Fridericia's formula (QTcF), time interval between the onset of the ECG wave P and the start of the QRS complex (PR), time interval between the beginning of Q wave and the termination of the S wave (QRS)

    Time frame: over 24 h after single administration

07

Study locations

2 sites
  • Biovirtus Research Site
    Nadarzyn, Mokra 7 05-830, Poland
  • Medical University in Lodz
    Lodz, Ul. Kopcińskiego 22 90-153, Poland
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2014
First posted
Jan 20, 2014
Start
Jan 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Last update
Oct 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02040597
Responsible party
Sponsor
First posted
Jan 20, 2014
Start date
Jan 2014
Primary completion
Apr 2015
Completion
Apr 2015
Last update
Oct 29, 2021

Study contacts

Piotr Kuna, MD
principal investigator · Medical University in Lodz
Kasia Jarus-Dziedzic, MD
principal investigator · Biovirtus

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Beclomethasone · Formoterol · Glycopyrrolate

Start the discussion